Even as Eli Lilly gets underway with its next major obesity launch in Foundayo, the FDA’s approval letter for the oral treatment shows lingering reservations about multiple “unexpected serious” risks potentially related to the drug. More: FDA tells Eli Lilly
read moreProtagonist Therapeutics-partnered Icotyde has the potential to become one of Johnson & Johnson’s “largest products ever,” CEO Joaquin Duato said on the company’s first-quarter earnings conference call. More: J&J, chasing 0B year, sports immunology ‘dual powerhouse’ of Tremfya and new
read moreThe AI will be used to analyze complex datasets and shrink R&D timelines, Novo said. It’ll additionally use the tech to seek efficiencies across manufacturing and corporate functions. More: Novo taps OpenAI to deploy AI across R&D, manufacturing and corporate
read moreThe FDA has scolded Pfizer over Facebook ads for the cancer drug Adcetris, accusing the Big Pharma of failing to adequately communicate the indication, contraindications and risks. More: Pfizer rebuked by FDA for misleading Adcetris ads on Facebook Source: fierce
read more© 1994 - 2026 B.M. Pharmaceuticals